You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
ExpreS2ion Biotechnologies - Presentation of Q1 Report 2024
You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.
ExpreS2ion Biotechnologies will release its Q1 results on 16 May 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies’ CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event.
ExpreS2ion Biotechnologies has commenced 2024 equipped with a clear new strategic direction of leveraging their platform to advance assets with shorter development timelines and less costly paths to value creation, and a solid Phase III validation of its ExpreS2™ antigen production system. The potential in the pipeline has further been validated during 2024, with completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This could be the focal point in the Q1 2024 reporting.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 11:15, 18 April 2024.